?? Exciting News! ?? We are thrilled to announce that Summit Therapeutics has earned the prestigious Great Places to Work? certification! This achievement reflects our commitment to creating an environment where innovation, collaboration, and personal growth thrive. At Summit, we are not just building groundbreaking therapies—we're building a company culture where our people are empowered, inspired, and valued. A huge thank you to our incredible team who make Summit such a special place to work. Together, we’re helping to shape the future! #GreatPlaceToWork #SummitTherapeutics #SMMTNewEra #Teamwork #Innovation #CompanyCulture #EmployeeExperience #ProudMoment
Summit Therapeutics, Inc.
生物技术研究
Miami,Florida 30,451 位关注者
Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health.
关于我们
- 网站
-
https://www.smmttx.com/
Summit Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Miami,Florida
- 类型
- 上市公司
- 创立
- 2003
- 领域
- Oncology、Clinical Trials和Health Care
地点
Summit Therapeutics, Inc.员工
动态
-
We're #hiring a new Director, Oncology Education in United States. Apply today or share this post with your network.
-
We're #hiring a new Senior Designer & Brand Strategist (Pharmaceutical Industry) in United States. Apply today or share this post with your network.
-
We're #hiring a new Senior Manager, Clinical Pharmacology & DMPK in Menlo Park, California. Apply today or share this post with your network.
-
We're #hiring a new Part-Time Contractor, Regulatory Operations in United States. Apply today or share this post with your network.
-
Congratulations to our partner, Akeso Inc., who announced groundbreaking results of their Phase III clinical study (HARMONi-2/AK112-303) with its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pembrolizumab monotherapy in the first-line treatment of PD-L1 positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC) have been published in?The Lancet. The Lancet is a prestigious international medical journal. You can view the publication here: https://lnkd.in/gAXsDUeX. #SMMTNewEra #SummitTherapeutics #ivonescimab #thelancet Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).
-
-
We're #hiring a new Clinical Trial Manager in Menlo Park, California. Apply today or share this post with your network.
-
Summit recognizes National Patient Safety Awareness Week from March 9th- March 15th, which aims to highlight the importance of improving safe care through healthcare. This year, The Center for Patient Safety’s theme is “Moving the Needle”; which is geared towards turning awareness into action with a multi-faceted approach that involves collaboration, engagement and continuous improvement to enhance patient safety. Join Team Summit in embracing the theme of “Moving the Needle” and fostering a culture of safety for patients and care teams. Together, we can make a difference! Summit is focused on resolving serious, unmet medical needs for the betterment of overall human health. We do this while also ensuring patient safety at every stage of development of our potential oncological treatments. To Learn More: https://www.smmttx.com/ #PSAW25 #SMMTNewEra #SummitTherapeutics
-
-
We're #hiring a new Director, Companion Diagnostics in United States. Apply today or share this post with your network.
-
We're #hiring a new Senior Manager Clinical Data Management in United States. Apply today or share this post with your network.